Olanzapine depot exposure in male rats: Dose-dependent lipogenic effects without concomitant weight gain

European Neuropsychopharmacology

Volumn 25, Issue 6, 2015, Pages 923-932

  Ferno J ^a,b   Ersland, K M ^a,b   Duus, I H ^a,b   Gonzalez Garcia I ^a,b   Fossan, K O ^a   Berge, R K ^b   Steen, V M ^a,b   Skrede, S ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Lipogenic; Male rat; Metabolism; Olanzapine depot formulation; Weight gain

Indexed keywords

CHOLESTEROL; OLANZAPINE; ALANINE AMINOTRANSFERASE; ANTIEMETIC AGENT; ASPARTATE AMINOTRANSFERASE; BENZODIAZEPINE DERIVATIVE; DELAYED RELEASE FORMULATION; GLUCOSE BLOOD LEVEL; LIPID; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ARTICLE; BROWN ADIPOSE TISSUE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HYPERPHAGIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEX DIFFERENCE; THERMOGENESIS; WEIGHT GAIN; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE; ADIPOCYTE; ANIMAL; BLOOD; BODY WEIGHT; DELAYED RELEASE FORMULATION; DIET RESTRICTION; DRUG EFFECTS; GENETICS; GLUCOSE BLOOD LEVEL; LIPOGENESIS; LIVER; METABOLISM; PATHOLOGY; PHARMACOLOGY; SPRAGUE DAWLEY RAT;

ADIPOCYTES; ALANINE TRANSAMINASE; ANIMALS; ANTIEMETICS; ASPARTATE AMINOTRANSFERASES; BENZODIAZEPINES; BLOOD GLUCOSE; BODY WEIGHT; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FASTING; FEMALE; LIPIDS; LIPOGENESIS; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; THERMOGENESIS; TRANSCRIPTION FACTORS;

EID: 84930271934     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.03.002     Document Type: Article

References (50)

1. Albaugh V.L., Henry C.R., Bello N.T., Hajnal A., Lynch S.L., Halle B., et al. Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity 2006, 14(1):36-51. Silver Spring.
2. Albaugh V.L., Judson J.G., She P., Lang C.H., Maresca K.P., Joyal J.L., et al. Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis. Mol. Psychiatry 2011, 16(5):569-581.
3. Albaugh V.L., Singareddy R., Mauger D., Lynch C.J. A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. PLoS One 2011, 6(8):e22662.
4. Albaugh V.L., Vary T.C., Ilkayeva O., Wenner B.R., Maresca K.P., Joyal J.L., et al. Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents. Schizophr. Bull. 2012, 38(1):153-166.
5. Aravagiri M., Teper Y., Marder S.R. Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm. Drug Dispos. 1999, 20(8):369-377.
6. Birkenaes A.B., Birkeland K.I., Engh J.A., Faerden A., Jonsdottir H., Ringen P.A., et al. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J. Clin. Psychopharm. 2008, 28(2):132-137.
7. Boyda H.N., Tse L., Procyshyn R.M., Honer W.G., Barr A.M. Preclinical models of antipsychotic drug-induced metabolic side effects. Trends Pharmacol. Sci. 2010, 31(10):484-497.
8. Brown S., Kim M., Mitchell C., Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br. J. Psychiatry 2010, 196(2):116-121.
9. Canfran-Duque A., Casado M.E., Pastor O., Sanchez-Wandelmer J., de la Pena G., Lerma M., et al. Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro. J. Lipid Res. 2013, 54(2):310-324.
10. Coccurello R., Moles A. Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol. Ther. 2010, 127(3):210-251.
11. Cooper G.D., Pickavance L.C., Wilding J.P., Harrold J.A., Halford J.C., Goudie A.J. Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J. Psychopharmacol. 2007, 21(4):405-413.
12. Correll C.U., Manu P., Olshanskiy V., Napolitano B., Kane J.M., Malhotra A.K. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009, 302(16):1765-1773.
13. Daumit G.L., Goff D.C., Meyer J.M., Davis V.G., Nasrallah H.A., McEvoy J.P., et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr. Res. 2008, 105(1-3):175-187.
14. Davoodi N., Kalinichev M., Clifton P.G. Comparative effects of olanzapine and ziprasidone on hypophagia induced by enhanced histamine neurotransmission in the rat. Behav. Pharmacol. 2008, 19(2):121-128.
15. Fell M.J., Anjum N., Dickinson K., Marshall K.M., Peltola L.M., Vickers S., et al. The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. Psychopharmacology 2007, 194(2):221-231. Berlin.
16. Ferno J., Raeder M.B., Vik-Mo A.O., Skrede S., Glambek M., Tronstad K.J., et al. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?. Pharmacogenomics J. 2005, 5(5):298-304.
17. Ferno J., Vik-Mo A.O., Jassim G., Havik B., Berge K., Skrede S., et al. Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology 2009, 203(1):73-84. Berlin.
18. Foley D.L., Morley K.I. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch. Gen. Psychiatry 2011, 68(6):609-616.
19. Gebhardt S., Haberhausen M., Heinzel-Gutenbrunner M., Gebhardt N., Remschmidt H., Krieg J.C., et al. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J. Psychiatr. Res. 2009, 43(6):620-626.
20. Girault E.M., Guigas B., Alkemade A., Foppen E., Ackermans M.T., la Fleur S.E., et al. Chronic treatment with olanzapine increases adiposity by changing fuel substrate and causes desensitization of the acute metabolic side effects. Naunyn-Schmiedebergs Arch. Pharmacol. 2014, 387(2):185-195.
21. Goudie A.J., Smith J.A., Halford J.C. Characterization of olanzapine-induced weight gain in rats. J. Psychopharmacol. 2002, 16(4):291-296.
22. Guesdon B., Denis R.G., Richard D. Additive effects of olanzapine and melanin-concentrating hormone agonism on energy balance. Behav. Brain Res. 2010, 207(1):14-20.
23. Hartfield A.W., Moore N.A., Clifton P.G. Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat. Psychopharmacology 2003, 167(2):115-122. Berlin.
24. Hartfield A.W., Moore N.A., Clifton P.G. Effects of atypical antipsychotic drugs on intralipid intake and cocaine-induced hyperactivity in rats. Neuropsychopharmacology 2006, 31(9):1938-1945.
25. Jassim G., Skrede S., Vazquez M.J., Wergedal H., Vik-Mo A.O., Lunder N., et al. Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. Psychopharmacology 2012, 219(3):783-794. Berlin.
26. Komossa K., Rummel-Kluge C., Hunger H., Schmid F., Schwarz S., Duggan L., et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. 2010, 3:CD006654.
27. Kroeze W.K., Hufeisen S.J., Popadak B.A., Renock S.M., Steinberg S., Ernsberger P., et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003, 28(3):519-526.
28. Laursen T.M., Munk-Olsen T., Agerbo E., Gasse C., Mortensen P.B. Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch. Gen. Psychiatry 2009, 66(7):713-720.
29. Leucht S., Cipriani A., Spineli L., Mavridis D., Orey D., Richter F., et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013.
30. McEvoy J.P., Lieberman J.A., Perkins D.O., Hamer R.M., Gu H., Lazarus A., et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am. J. Psychiatry 2007, 164(7):1050-1060.
31. McNamara R.K., Jandacek R., Rider T., Tso P., Cole-Strauss A., Lipton J.W. Atypical antipsychotic medications increase postprandial triglyceride and glucose levels in male rats: relationship with stearoyl-CoA desaturase activity. Schizophr. Res. 2011, 129(1):66-73.
32. Minet-Ringuet J., Even P.C., Goubern M., Tome D., de Beaurepaire R. Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration. Appetite 2006, 46(3):254-262.
33. Minet-Ringuet J., Even P.C., Guesdon B., Tome D., de Beaurepaire R. Effects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection. Behav. Brain Res. 2005, 163(2):204-211.
34. Minet-Ringuet J., Even P.C., Lacroix M., Tome D., de Beaurepaire R. A model for antipsychotic-induced obesity in the male rat. Psychopharmacology 2006, 187(4):447-454. Berlin.
35. Newcomer J.W., Meyer J.M., Baker R.A., Eudicone J.M., Pikalov A., Vester-Blokland E., et al. Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine. Schizophr. Res. 2008, 106(2-3):300-307.
36. Nordentoft M., Wahlbeck K., Hallgren J., Westman J., Osby U., Alinaghizadeh H., et al. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS One 2013, 8(1):e55176.
37. Osborn D.P., Levy G., Nazareth I., Petersen I., Islam A., King M.B. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom[U+05F3]s general practice rsearch database. Arch. Gen. Psychiatry 2007, 64(2):242-249.
38. Perez-Iglesias R., Crespo-Facorro B., Martinez-Garcia O., Ramirez-Bonilla M.L., Alvarez-Jimenez M., Pelayo-Teran J.M., et al. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population. Schizophr. Res. 2008, 99(1-3):13-22.
39. Pouzet B., Mow T., Kreilgaard M., Velschow S. Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol. Biochem. Behav. 2003, 75(1):133-140.
40. Raeder M.B., Ferno J., Vik-Mo A.O., Steen V.M. SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects?. Mol. Cell. Biochem. 2006, 289(1-2):167-173.
41. Robertson M.D., McMullin M.M. Olanzapine concentrations in clinical serum and postmortem blood specimens--when does therapeutic become toxic?. J. Forensic Sci. 2000, 45(2):418-421.
42. Rummel-Kluge C., Komossa K., Schwarz S., Hunger H., Schmid F., Lobos C.A., et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 2010, 123(2-3):225-233.
43. Shobo M., Yamada H., Koakutsu A., Hamada N., Fujii M., Harada K., et al. Chronic treatment with olanzapine via a novel infusion pump induces adiposity in male rats. Life Sci. 2011, 88(17-18):761-765.
44. Shobo M., Yamada H., Mihara T., Kondo Y., Irie M., Harada K., et al. Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone. Behav. Brain Res. 2011, 216(2):561-568.
45. Skrede S., Ferno J., Vazquez M.J., Fjaer S., Pavlin T., Lunder N., et al. Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. Int. J. Neuropsychopharmacol. 2012, 15(2):163-179.
46. Skrede S., Martins L., Berge R.K., Steen V.M., Lopez M., Ferno J. Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects. Int. J. Neuropsychopharmacol. 2014, 17(1):91-104.
47. Skrede S., Steen V.M., Ferno J. Antipsychotic-induced increase in lipid biosynthesis: activation through inhibition?. J. Lipid Res. 2013, 54(2):307-309.
48. Stefanidis A., Verty A.N., Allen A.M., Owens N.C., Cowley M.A., Oldfield B.J. The role of thermogenesis in antipsychotic drug-induced weight gain. Obesity 2009, 17(1):16-24. Silver Spring.
49. Teff K.L., Rickels M.R., Grudziak J., Fuller C., Nguyen H.L., Rickels K. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes 2013, 62(9):3232-3240.
50. Vidarsdottir S., de Leeuw van Weenen J.E., Frolich M., Roelfsema F., Romijn J.A., Pijl H. Effects of olanzapine and haloperidol on the metabolic status of healthy men. J. Clin. Endocrinol. Metab 2009.